Comment
doi: 10.1016/S1470-2045(17)30338-8.
Epub 2017 Jun 9.
Ascending role of next-generation ALK inhibitors
Affiliations
- PMID: 28602777
- DOI: 10.1016/S1470-2045(17)30338-8
Item in Clipboard
Comment
Ascending role of next-generation ALK inhibitors
Lancet Oncol.
2017 Jul.
No abstract available
Comment on
-
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9. Lancet Oncol. 2017. PMID: 28602779 Clinical Trial.
Similar articles
-
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.Oncotarget. 2017 Mar 28;8(13):21903-21917. doi: 10.18632/oncotarget.15746. Oncotarget. 2017. PMID: 28423535 Free PMC article.
-
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.Med Oncol. 2018 Apr 17;35(5):72. doi: 10.1007/s12032-018-1133-4. Med Oncol. 2018. PMID: 29666949 Review.
-
ALK inhibitors: plateauing systemic and intracranial activity?Lancet Oncol. 2016 Apr;17(4):404-406. doi: 10.1016/S1470-2045(16)00025-5. Epub 2016 Mar 11. Lancet Oncol. 2016. PMID: 26973321 No abstract available.
-
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.Expert Opin Investig Drugs. 2017 Jun;26(6):713-722. doi: 10.1080/13543784.2017.1324572. Epub 2017 May 18. Expert Opin Investig Drugs. 2017. PMID: 28463570 Review.
-
Crizotinib in ALK-positive lung cancer.Lancet Oncol. 2012 Oct;13(10):962-3. doi: 10.1016/S1470-2045(12)70375-3. Epub 2012 Sep 4. Lancet Oncol. 2012. PMID: 22954506 No abstract available.
Cited by
-
Treating ALK-positive non-small cell lung cancer.Ann Transl Med. 2018 Apr;6(8):141. doi: 10.21037/atm.2017.11.34. Ann Transl Med. 2018. PMID: 29862230 Free PMC article. Review.
-
Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.J Thorac Dis. 2017 Sep;9(9):2812-2818. doi: 10.21037/jtd.2017.08.79. J Thorac Dis. 2017. PMID: 29221246 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
